Search our Database of Scientific Publications and Authors

I’m looking for a
    [Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.]
    Arch Esp Urol 2017 Jul;70(6):561-569
    Servicio de Urología. Hospital Universitario Puerta del Mar. Cádiz. España.
    Objectives: To determine the tolerability, persistenceand satisfaction of patients with overactive bladder syndrome (OAB) treated with transdermal oxybutynin (OXY-TDS).

    Methods: Observational, retrospective, multicenter study, in patients with OAB who had started treatment with OXY-TDS at least 12 months before their inclusion. Tolerability was evaluated by number, severity criteria, resolution type of adverse reactions, and cognitive function with Mini-Mental State Examination (MMSE), at 1 year of treatment. The patients who remained under treatment during the observation period were considered persistent. Patient satisfaction was evaluated using an ad hoc questionnaire.

    Results: The clinical history of 105 patients was evaluated. 92.4% were women. The mean age of all the patients was 59.4 ± 11.8 years. After 12 months of treatment, dry mouth was present in 5.7% of patients and 27.6% had mild or moderate adverse reactions in the area of application. The persistence in treatment was 55.2%. The use of the OXY-TDS was considered comfortable or very comfortable by 92.9% of patients.

    Conclusions: The study performed in patients with OAB shows that OXY-TDS provides low incidence of systemic adverse effects, including dry mouth, high persistence, improved adherence rates and high satisfaction of patients after one year of treatment.

    Similar Publications

    Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    J Manag Care Pharm 2008 Apr;14(3):291-301
    Xcenda, LLC, Cincinnati, OH 45255, USA. anna.dsouza
    Background: Pharmacotherapy constitutes an important adjunct to behavioral therapy for the treatment of overactive bladder (OAB). Tolterodine and oxybutynin are commonly prescribed drugs for OAB treatment that exert their beneficial effect by suppressing bladder muscle contractions. However, high discontinuation rates have been observed for these drugs in clinical trials, as well as in real-world settings, in part due to adverse effects. Read More
    Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    BJU Int 2007 Apr 20;99(4):836-44. Epub 2006 Dec 20.
    Evanston Continence Center, Evanston Northwestern Healthcare, Northwestern University, Feinburg School of Medicine, Evanston IL, USA.
    Objective: To assess health-related quality-of-life (HRQoL) and safety with the oxybutynin transdermal system (OXY-TDS) (Oxytrol), Watson Pharma, Corona, CA, USA) in the Multicentre Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin (MATRIX) study, as HRQoL measurements are increasingly important in evaluating pharmacotherapy for overactive bladder (OAB).

    Patients And Methods: This randomized, open-label, community-based study enrolled 2878 participants aged >/=18 years who had been given a diagnosis of OAB. The 327 study sites were representative of various practice types. Read More
    The value of oxybutynin in transdermal patches for treating overactive bladder.
    Actas Urol Esp 2015 Dec 28;39(10):599-604. Epub 2015 Aug 28.
    Gebro Pharma, Barcelona, España.
    Context: There is currently a broad therapeutic arsenal of drugs for treating overactive bladder syndrome (OAB). However, there is still a need for new compounds and for improving known drugs in terms of efficacy, compliance and tolerability.

    Objective: To report the scientific evidence on the safety and efficacy of transdermal oxybutynin (OXY-TDS) for treating OAB. Read More
    Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Int J Clin Pract 2008 Jan;62(1):167-70
    Department of Urology, Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.
    Overactive bladder (OAB) syndrome affects millions of people worldwide. In addition to adversely affecting quality of life, the direct and indirect costs in managing patients with OAB incur a substantial financial burden on health services. Among the approved anticholinergics for treating OAB, oxybutynin is the most extensively studied drug in clinical trials. Read More